Title: A multicenter, phase II study in patients with first line NSCLC, or recurrent PD-X refractoryNSCLC or with recurrent HNSCC receiving Eftilagimod Alpha in combination withPembrolizumab (TACTI-002)Authors: Martin Forster; Frederic Triebel; Christian Mueller; Chrystelle Brignone; Tatsiana Skrahina
I think I might be underestimating the possibilities of this abstract.......We have authors, therefore there must be a story....
Martin Forster is lead author, a name not previously associated with PRR/IMM that I can recall,Tatsiana the same, the
other 3 we know......I'm intrigued now, what could it be, been accepted as a late breaking abstract.....Have I missed
something somewhere?
Q4/2018...What will it bring?, page-9
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.020(6.06%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.3¢ | 30.5¢ | $1.905M | 6.153M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 13147 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 101130 | 2 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
